Login
$CNTX
$0.18 +$0.01 (5.61%) After hours

$CNTX SEC Filings

Filed On Filing
10 Nov 2026 8-K: Regulation FD Disclosure; Other Events

November 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

10 Nov 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 8-K: Regulation FD Disclosure

August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

05 Aug 2026 10-Q
31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Co...

31 Jul 2026 SCHEDULE 13G/A
27 Jul 2026 SCHEDULE 13G
26 Jun 2026 Form 4: Pasternak Andy, Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 Form 4: Stacey Jennifer Evans, Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 Form 4: West Linda, Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 Form 4: Smith Karen L., Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 Form 4: Walker Luke Nathaniel, Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 Form 4: Kantoff Philip W., Director

Granted 45,000 Stock Option (right to buy)

26 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Context Therapeutics Inc. (the “Company”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

15 Jun 2026 8-K: Regulation FD Disclosure; Other Events

June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors

18 May 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corp...

15 May 2026 SCHEDULE 13G/A
14 May 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support